Insights from Veeva Projected Prescription and Procedure Data: Commercial Momentum and Market Adoption

Powered by projected prescription and procedure data in Compass Prescriber and National, this report shows estimated unique patient starts and healthcare providers (HCPs) across recent novel therapy launches.

Compass includes non-retail channels, offering a more complete picture of commercial momentum. The performance metrics below represent cumulative, launch-to-date totals.

Brand Manufacturer Disease Area Cumulative
Patient Starts		 Cumulative
HCP Counts
Baxfendy AstraZeneca (AZ) Hypertension 1,411 618
Exdensur GSK Asthma 805 229
Icotyde Janssen (J&J Innovative Medicine) Psoriasis 2,506 918
Inluriyo Lilly Breast Cancer 1,463 647
Keytruda Qlex Merck Multiple Oncology Indications 8,747 1,225
Lynkuet Bayer Menopause 19,107 7,809
Modeyso Jazz Pharma Brain Cancer 505 115
Myqorzo Cytokinetics Cardiomyopathy 1,150 232
Rhapsido Novartis Urticaria 6,392 2,314
Voyxact Otsuka Immunoglobulin A Nephropathy 1,157 205
Data through June 30, 2026

Additional recent launches also available:

  • Idvynso (Merck)
  • Lifyorli (Corcept Therapeutics)
  • Qivigy (Kedrion Biopharma)
  • Vybrique (IBSA Pharma)
  • Yuvezzi (Tenpoint Therapuetics)

To learn more about these launch brands or explore custom market analysis, contact anthony.billinger@veeva.com.

Veeva Compass Prescriber & Compass National are syndicated data products that leverage two patented projection methodologies to estimate prescription, procedure, and patient volume within the United States. Centers for Medicare & Medicaid Services (CMS) drug utilization data is accessed through Virtual Research Data Center (VRDC), and leveraged as part of these methodologies. These estimates are fully refreshed on a weekly and monthly basis.
Let's Partner

Interested in learning more about
how Veeva can help?

Contact Us Download PDF